Abstract

The sonic hedgehog (Shh) pathway is highly activated in a variety of malignancies and plays important roles in tumorigenesis, tumor growth, drug resistance, and metastasis. Our recent study showed that the inhibitors of the Shh pathway such as cyclopamine (CP), a Smothened (SMO) inhibitor, and GANT61, a Gli1 inhibitor, have modest inhibitory effects on thyroid tumor cell proliferation and tumor growth. The objective of this study was to determine whether autophagy was induced by inhibition of the Shh pathway and could negatively regulate GANT61-induced apoptosis. Here we report that inhibition of the Shh pathway by Gli1 siRNA or by cyclopamine and GANT61 induced autophagy in SW1736 and KAT-18 cells, two anaplastic thyroid cancer cell lines; whereas Gli1 overexpression suppressed autophagy. Mechanistic investigation revealed that inhibition of the Shh pathway activated TAK1 and its two downstream kinases, the c-Jun-terminal kinase (JNK) and AMP-activated protein kinase (AMPK). GANT61-induced autophagy was blocked by TAK1 siRNA and the inhibitors of TAK1 (5Z-7-oxozeaenol, 5Z), JNK (SP600125), and AMPK (Compound C, CC). Inhibition of autophagy by chloroquine and 5Z and by TAK1 and Beclin-1 siRNA enhanced GANT61-induced apoptosis and its antiproliferative activity. Our study has shown that inhibition of the Shh pathway induces autophagy by activating TAK1, whereas autophagy in turn suppresses GANT61-induced apoptosis. We have uncovered a previously unrecognized role of TAK1 in Shh pathway inhibition-induced autophagy and apoptosis.

Highlights

  • Thyroid cancer is one of the most common endocrine malignancies[1]

  • To investigate if increased LC3 lipidation was due to the induction of autophagy or due to the stall of the autophagy flux, we investigated the effect of bafilomycin (Baf) and chloroquine (CQ) on GANT61induced autophagy

  • Confocal microscopy revealed that GANT61 (10 μM), bafilomycin (10 nM), and CQ (10 μM) all induced the formation of green fluoresce protein (GFP)tagged LC3 puncta perinuclearly distributed in SW1736 cells (Fig. 1E)

Read more

Summary

Introduction

Thyroid cancer is one of the most common endocrine malignancies[1]. Thyroid cancers are divided into several different tumor types based on the pathological characteristics and the origins of tumor cells[2]. Well differentiated papillary (PTCs) and follicular (FTCs) thyroid cancers are derived from thyroid follicular epithelial cells and may progress into poorly differentiated or anaplastic (MTCs) are derived from the C cells of the thyroid gland. Thyroid hormone therapy, and radioiodine can cure most differentiated PTCs and FTCs but are not effective for poorly differentiated thyroid cancer[3]. 15–20% of thyroid cancer patients develop recurrence in their lifetime[1]. There is no effective therapy to treat ATC. The mean survival of ATC patients is only 2–6 months[4]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call